DBCO PEG Maleimide (DBCO-PEG-Mal): Selection & Usage Guide

DBCO PEG Maleimide, DBCO-PEG-Mal is a heterobifunctional PEG linker bearing a dibenzocyclooctyne (DBCO) group for copper-free strain-promoted azide–alkyne cycloaddition (SPAAC) at one terminus and a maleimide group for selective covalent reaction with free thiols at the other, enabling modular, bioorthogonal dual-conjugation strategies.

Functional Groups

DBCO (azide-reactive, SPAAC) and Maleimide (thiol-reactive)

Reaction Conditions

Copper-free; maleimide-thiol reaction optimal at pH 6.5–7.5

PEG Spacer Role

Improves aqueous solubility, reduces steric hindrance, and extends linker flexibility

Bioorthogonal Compatibility

DBCO reacts selectively with azides without metal catalysts, compatible with live-cell labeling

Storage Recommendation

Store desiccated at -20°C, protected from moisture and light; avoid repeated freeze-thaw cycles

Typical Applications

ADC synthesis, nanoparticle surface functionalization, protein bioconjugation, biomaterial engineering

What Is DBCO-PEG-Mal and How Does It Work?

DBCO PEG Maleimide (DBCO-PEG-Mal) is a heterobifunctional polyethylene glycol (PEG) reagent designed for two orthogonal bioconjugation reactions. The DBCO (dibenzocyclooctyne) moiety undergoes a strain-promoted azide–alkyne cycloaddition (SPAAC) with azide-bearing molecules under physiological conditions without the need for a copper catalyst, making it fully biocompatible. The maleimide terminus reacts selectively and rapidly with free sulfhydryl (–SH) groups present on cysteine residues or thiolated substrates via a Michael addition mechanism.

The central PEG chain serves as a hydrophilic, flexible spacer that (1) enhances aqueous solubility of the overall conjugate, (2) reduces steric clashes between the two biomolecular partners, and (3) minimizes non-specific interactions. By combining two orthogonal reactive handles in a single molecule, DBCO-PEG-Mal enables the sequential or simultaneous attachment of two distinct biomolecular entities—such as an azide-modified drug and a thiol-containing antibody—without cross-reactivity between the two conjugation chemistries.

Protocol: Step-by-Step Conjugation Using DBCO-PEG-Mal

Materials required: DBCO-PEG-Mal (D163532), thiol-bearing molecule (e.g., reduced antibody or thiolated peptide), azide-functionalized molecule, anhydrous DMSO or DMF for stock preparation, phosphate or HEPES buffer (pH 6.5–7.5), desalting columns or dialysis equipment, analytical HPLC or mass spectrometry for verification.

Step 1 – Prepare stock solution: Dissolve lyophilized DBCO-PEG-Mal in anhydrous DMSO or DMF to make a concentrated stock (e.g., 10–50 mM). Aliquot immediately and store at -20°C under inert gas (argon or nitrogen). Avoid aqueous stock solutions for long-term storage as maleimide hydrolysis will reduce reactivity over time.

Step 2 – Thiol conjugation (maleimide reaction): Reduce disulfide bonds in the target protein (if needed) using TCEP or DTT, then remove the reducing agent by desalting. React the thiol-bearing molecule with DBCO-PEG-Mal in reaction buffer at pH 6.5–7.5 using a molar excess of linker (typically 3–10 equivalents). Incubate at room temperature for 1–2 hours with gentle mixing. Remove unreacted linker by size-exclusion chromatography or dialysis.

Step 3 – SPAAC reaction (DBCO–azide): Add the azide-functionalized molecule to the DBCO-PEG-Mal–thiol conjugate purified in Step 2. Perform the SPAAC reaction in aqueous buffer at room temperature or 37°C for 1–12 hours depending on azide concentration and desired conversion efficiency. No catalyst is required.

Step 4 – Purification and analysis: Purify the final conjugate by size-exclusion chromatography, affinity chromatography, or dialysis. Confirm conjugation by SDS-PAGE, analytical HPLC, or mass spectrometry.

Note: Perform all maleimide reactions under slightly acidic to neutral conditions (pH 6.5–7.5) to maximize thiol selectivity and minimize competing maleimide hydrolysis or amine reaction.

Key Applications of DBCO-PEG-Mal in Research

Antibody–Drug Conjugate (ADC) Synthesis: DBCO-PEG-Mal is widely used as a bifunctional linker in ADC development. The maleimide group enables site-specific attachment to reduced interchain cysteine residues on antibodies, while the DBCO arm can be conjugated to an azide-modified cytotoxic payload, providing a defined drug-to-antibody ratio (DAR) and homogeneous conjugate.

Nanoparticle Surface Functionalization: Thiol-decorated nanoparticles (gold, silica, lipid nanoparticles) can be functionalized with DBCO-PEG-Mal via the maleimide–thiol reaction, appending a DBCO handle for subsequent copper-free attachment of azide-modified targeting ligands, imaging agents, or therapeutic molecules.

Bioorthogonal Live-Cell Labeling: Because SPAAC proceeds without toxic copper catalysts, DBCO-PEG-Mal-modified probes can be used to label azide-bearing metabolically incorporated unnatural sugars or amino acids on living cell surfaces, enabling real-time tracking of glycoproteins, lipids, or other biomolecules.

Biomaterial and Hydrogel Engineering: The dual-reactive nature of DBCO-PEG-Mal supports the fabrication of crosslinked hydrogels and functionalized scaffolds for tissue engineering applications, where independent control of two conjugation chemistries is critical for spatially defined biofunctionalization.

Selection, Handling, and Storage Guidelines

PEG chain length selection: DBCO-PEG-Mal is available with varying PEG chain lengths (e.g., PEG4, PEG8, PEG12, and higher MW PEG). Shorter PEG spacers offer less steric shielding but may be preferred where compact linker size is critical. Longer PEG chains improve water solubility and provide greater separation between the two conjugated biomolecules, often beneficial for minimizing steric interference in large-molecule conjugates such as antibodies. Consult product specifications (D163532) for available PEG MW options.

Solvent compatibility: DBCO-PEG-Mal is soluble in DMSO, DMF, and aqueous buffers. For aqueous reactions, add the DMSO stock at ≤10% v/v final concentration to avoid protein denaturation. Ensure the target biomolecule is compatible with the chosen co-solvent.

Maleimide stability: Maleimide groups are susceptible to hydrolysis at neutral-to-basic pH, forming non-reactive maleamic acid. Prepare fresh aqueous working solutions immediately before use and keep reaction times as short as practically achievable. Maintain reaction pH between 6.5 and 7.5 for optimal thiol selectivity.

Storage: Store lyophilized or neat DBCO-PEG-Mal desiccated at -20°C, protected from light and atmospheric moisture. Once dissolved in organic solvent, aliquot into single-use portions under inert gas and store at -20°C. Avoid repeated freeze-thaw cycles. Check product datasheet (D163532) for lot-specific stability data.

Troubleshooting Common Issues

Low conjugation efficiency (maleimide–thiol step): Verify that free thiols are present and not oxidized back to disulfides. Re-reduce the thiol-containing molecule with fresh TCEP immediately before the reaction and desalt thoroughly to remove TCEP, which can compete with maleimide. Ensure pH is in the optimal range (6.5–7.5). Increase molar excess of DBCO-PEG-Mal or extend incubation time.

Low SPAAC conversion (DBCO–azide step): Confirm the azide substrate is present at sufficient concentration and has not degraded. DBCO–azide SPAAC is generally slower than copper-catalyzed CuAAC; extend reaction time or increase temperature to 37°C. Verify that the DBCO group has not been quenched by thiol contaminants in the buffer (avoid DTT or 2-ME in buffers used for SPAAC reactions).

Aggregate formation: PEGylated conjugates may aggregate if the hydrophobic DBCO moiety causes self-association at high concentrations. Reduce protein concentration, add a low percentage of non-ionic detergent (e.g., 0.01–0.05% Tween-20), or use a longer PEG chain to improve solubility.

Loss of maleimide reactivity: If conjugation efficiency drops after reagent storage, maleimide hydrolysis may have occurred. Always use freshly dissolved reagent aliquots and verify reactivity with a model thiol substrate (e.g., N-acetyl-cysteine) before committing to precious biological samples.

Frequently asked questions

What is the difference between DBCO-PEG-Mal and other DBCO-PEG reagents?

DBCO-PEG-Mal is a heterobifunctional reagent combining DBCO (azide-reactive) and maleimide (thiol-reactive) groups, enabling two orthogonal conjugations in a single linker. In contrast, homobifunctional DBCO-PEG-DBCO or monofunctional DBCO-PEG-amine reagents carry identical or only one type of reactive group, limiting them to single-chemistry conjugation strategies. The dual orthogonal functionality of DBCO-PEG-Mal is particularly valuable for assembling multi-component bioconjugates.

Can DBCO-PEG-Mal be used in live-cell experiments?

Yes. The DBCO-mediated SPAAC reaction is copper-free and biocompatible, making it suitable for use with living cells that display azide-modified biomolecules (e.g., metabolically labeled glycoproteins). However, the maleimide group reacts with endogenous thiols, so care should be taken to pre-conjugate the maleimide end to the desired thiol-bearing probe before introducing the DBCO-functionalized reagent to living cells to minimize off-target reactivity.

What buffers are compatible with the maleimide–thiol conjugation reaction?

Phosphate-buffered saline (PBS, pH 7.2), sodium phosphate buffer (pH 6.5–7.2), and HEPES buffer (pH 7.0–7.5) are all compatible. Avoid buffers containing free thiols (e.g., DTT, 2-mercaptoethanol) or primary amines in high concentrations (e.g., Tris, glycine) as these will compete with the thiol substrate or react with the maleimide group. Also avoid strongly basic conditions (pH >8) where maleimide hydrolysis becomes significant.

How do I verify successful conjugation with DBCO-PEG-Mal?

Common verification methods include SDS-PAGE (a molecular weight shift indicates successful PEGylation or payload attachment), mass spectrometry (confirms conjugate mass and stoichiometry), and analytical HPLC (shows change in retention time or peak profile). For fluorescent or UV-absorbing payloads, spectrophotometric analysis can quantify incorporation. A DBCO-specific UV absorbance at approximately 309 nm can be used to monitor consumption of the DBCO group during the SPAAC reaction.

Is DBCO-PEG-Mal suitable for GMP or clinical manufacturing?

D163532 is supplied as a research-grade reagent intended for laboratory research use only. For clinical or GMP manufacturing applications, a GMP-grade certified supply chain and additional quality documentation (certificates of analysis, residual solvent testing, etc.) would be required. Please contact Aladdin Scientific for custom or GMP-grade inquiries.

References

1. Agard NJ, Prescher JA, Bertozzi CR. A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems. J Am Chem Soc. 2004;126(46):15046-15047. doi:10.1021/ja044996f
2. Mather BD, Viswanathan K, Miller KM, Long TE. Michael addition reactions in macromolecular design for emerging technologies. Prog Polym Sci. 2006;31(5):487-531. doi:10.1016/j.progpolymsci.2006.03.001
3. Bargh JD, Isidro-Llobet A, Parker JS, Spring DR. Cleavable linkers in antibody-drug conjugates. Chem Soc Rev. 2019;48(16):4361-4374. doi:10.1039/C8CS00676H
4. Debets MF, van Berkel SS, Dommerholt J, et al. Bioconjugation with strained alkenes and alkynes. Acc Chem Res. 2011;44(9):805-815. doi:10.1021/ar200059z

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.